Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417044 | 1.00 | MCHR1 (0.65) | MCHR1LSS | |
| SCHEMBL415939 | 0.79 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL415938 | 0.79 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL415937 | 0.79 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL356163 | 0.79 | MCHR1 (0.62) | MCHR1 | |
| SCHEMBL10082903 | 0.74 | MCHR1 (0.69) | MCHR1 | |
| SCHEMBL22534359 | 0.72 | PNMT (0.41) | — | |
| SCHEMBL31473533 | 0.72 | TP53 (0.53) | MCHR1 | |
| SCHEMBL417145 | 0.72 | MCHR1 (0.69) | MCHR1 | |
| SCHEMBL421737 | 0.72 | MCHR1 (0.69) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552199-B2 | Substituted indanes, method for the production thereof, and use thereof as drugs | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-20120022039-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2012-01-26 | — | — | US | disclosed |
| EP-2396298-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092154-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022039-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | MCHR1, MCHR2, IDO1 | MCHR1 1/4885LSS 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.